
	Application Number: 09/541,795	AR#/2/0
	Filing Date: March 31, 2000	M. C.Sitte
	First Named Inventor: James LINK et al.	TECH MAR 25
	Group Art Unit: 1624	CENTED COO3
	Examiner: Sudhaker Patel	1600/20
	Attorney Docket Number: 09095.0005	, -900

		~~~	$\mathcal{J}_{\mathcal{I}}$		1270			
841	.21	M	ii REQ	UEST FOR	Filing Date: March 31, 2000			
CONTINUED EXAMINATION (RCE) TRANSMITTAL  Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000 provides for continued examination of a utility or plant application					First Named Inventor: James LINK et al.			
					Group Art Unit: 1624			
					Examiner: Sudhaker Patel  Attorney Docket Number: 09095,0005			
	See	The A		r after June 8, 1995. ntors Protection Act of 1999 (AIPA)	Attorney Docket Number: 09095.0005			
					Attorney Customer Number: 22,852			
Thi	s is a	Reque	est for Continue	d Examination (RCE) under 37 C.F.R. § 1.1	14 of the above-identified application.			
Not	Note: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53(d) instead of a RCE to be eligible for patent term adjustment provisions of the AIPA. See "Changes to Application Examination and Provisional Application Practice," Interim Rule, 65 Fed. Reg. 14865 (March 20, 2000). Off. Gaz. Pat. Office 47 (April 11, 2000), which established RCE practice.							
1.	Su	bmiss	sion required	under 37 C.F.R. § 1.114:				
	a.		Previously s	submitted				
		i.		Consider the amendment(s)/reply	after final under 37 C.F.R. § 1.116 previously filed on			
	,.,	ii.		Consider the arguments in the Ap	peal Brief of Reply Brief previously filed on			
		iii.		Other				
	b.		Enclosed:					
		i.	$\boxtimes$	Amendment &/or Reply				
		ii.		Affidavit(s)/Declaration(s)				
		iii.		Information Disclosure Statement				
		iv.		Other				
2.	Mis	scella	neous					
	a.		Suspension of action on the above-mentioned application is requested under 37 C.F.R. § 1.103(c) for a period of months. (Period of suspension shall not exceed 3 months; fee under 37 C.F.R. § 1.17(i) required.)					
	b.		Other					
				·				
3.	Fe	es			03/24/2003 BHGUYEH1 00000010 09541795			
	a.	$\boxtimes$	The filing fe	e is calculated as follows:	02 FC:1801 750.00 0P			
	i. \$750.00 RCE fee required under 37 C.F.R. § 1.17(e)							
	ii. Petition for extension of time for (3 Months) \$930.00							
	iii. Other							
b.								
c.   The Commissioner is authorized to charge any deficiencies in the filing fees, or credit any overpayments to Deposit Account No. 06-0916.								
				Signature of Applica	int, Attorney, or Agent Required			
Na	me:	Cha	rles D. Nieby	lski	Reg. No.: 46,116			
Signature: Date: March 21, 2003								
Certificate of Mailing or Transmission								
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, BOX RCE, Washington, D.C. 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on:								
	me:							
Signature: Date:								







## IN THE UNITED STATES PATENT AND TRADEMARK Off文

In	re	App	lication	of:
	. •	, ,PP		• • • •

James LINK et al.

Application No.: 09/541,795

Filed: March 31, 2000

For: CELL ADHESION-INHIBITING

ANTIINFLAMMATORY AND IMMUNE-

SUPPRESSIVE COMPOUNDS

Group Art Unit: 1624

Examiner: Sudhaker Patel

## **BOX RCE**

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

## SUBMISSION UNDER 37 C.F.R. § 1.114

In reply to the final Office Action mailed on September 23, 2002, Applicants file herewith a Request for Continued Examination and submit the following arguments in accordance with the submission requirements of 37 C.F.R. § 1.114. The period for filing this Request for Continued Examination has been extended by the concurrently filed Petition for a Three-Month Extension of Time to Monday, March 24, 2003. Thus, this Response is timely filed.

## STATUS OF THE CLAIMS

Claims 1-60 are pending in this application. No claims have been amended, and no new matter has been added. Claims 2, 24, and 25 have been withdrawn as being directed to a non-elected invention. All claims remain rejected.

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com